
The FDA has approved Infilbray (venglustat), a once-daily oral medication that crosses the blood-brain barrier to treat neurological symptoms of Type 3 Gaucher disease (GD3) in adults and children over 15 kg. GD3 is a rare genetic disorder causing progressive neurological and systemic decline. Approval was based on positive phase 3 trial results showing Infilbray's superiority over enzyme replacement therapy in improving cognitive and motor functions. Sanofi plans further regulatory submissions worldwide, marking a significant advance for patients with this challenging condition.
Following the FDA approval of Sanofi's Infilbray for Type 3 Gaucher disease, Sanofi's stock (SNY) is trading at USD 47.01 on Pluang as of Nov 19, 2026 05:11 WIB, down 1.09% for the day. The company holds a market cap of $114.30 billion and offers a dividend yield of 5.09%, with a typical hold time of 96 days among Pluang investors.